Molnupiravir

莫诺拉韦

Report date: 2024/05/15 12:00:57
NME

Base Information

Drug NameMolnupiravir
Drug Alias Name莫奈拉韦LagevrioLAGEVRIO利卓瑞Molxvir +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionVirus replication inhibitorsRNA-directed RNA polymerase inhibitors
TargetsRNA-directed RNA polymerase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyHepatic Insufficiency +[5] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2021/11/04
Country/TerritoryBulgariaCanadaUnited States +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEmory University
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Fosun Pharmaceutical (Group) Co LtdRidgeback Biotherapeutics LpChina National Pharmaceutical Group Co +[14] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyHepatic Insufficiency +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeJ05AX
Related LinksWikipediaDrugBankKEGG